Demetrios Braddock was born in Tennessee and began his education in Music Performance at Indiana School of Music (classical violin). After two years, he transferred to the University of Chicago, where he completed studies in Chemistry (B.A.), and Biochemistry and Medicine (MD/PhD). He did his residency in Anatomic Pathology at the NIH, where he also completed postdoctoral studies in Biophysical Chemistry. Demetrios has been at Yale since 2004, where he practices Hematophatology and leads a laboratory that studies Rare Diseases. His laboratory recently described a biologic therapeutic for a lethal neonatal disease of vascular calcification called ‘Generalized Arterial Calcification of Infancy’ or GACI. Demetrios is the Scientific founder of ‘Inozyme’, a start-up company founded with Yale Faculty Enrique De La Cruz and Joseph Schlessinger, to translate biologic therapy described in his laboratory into patients.